LFG
VRDN icon

Larson Financial Group’s Viridian Therapeutics VRDN Stock Holding History

Larson Financial Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143K Buy
7,782
+6,860
+744% +$111K ﹤0.01% 998
2026
Q1 		$18K Buy
922
+9
+1% +$267 ﹤0.01% 1906
2025
Q4 		$28.4K Sell
913
-1,494
-62% -$41K ﹤0.01% 1521
2025
Q3 		$51.9K Buy
+2,407
New +$43.4K ﹤0.01% 1145
2025
Q2 		– Sell
-8
Closed -$108 – 3510
2025
Q1 		$108 Buy
+8
New +$136 ﹤0.01% 2900

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Larson Financial Group's VRDN Position: Q2 2026 in Review

Larson Financial Group increased its Viridian Therapeutics (VRDN) stake by 744% in Q2 2026, buying an estimated $111K and bringing the position to 7,782 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #998.

Larson Financial Group first reported a position in VRDN in Q1 2025 and has held it in 5 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Larson Financial Group held 7,782 shares of Viridian Therapeutics worth $143K as of Q2 2026.
  • Larson Financial Group bought 6,860 Viridian Therapeutics shares in Q2 2026, an estimated $111K.
  • Viridian Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #998 holding.
  • Larson Financial Group first reported a position in Viridian Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.